Top

Published in:

01-12-2009

Are prediction models for Lynch syndrome valid for probands with endometrial cancer?

Authors: Floor J. Backes, Heather Hampel, Katherine A. Backes, Luis Vaccarello, George Lewandowski, Jeffrey A. Bell, Gary C. Reid, Larry J. Copeland, Jeffrey M. Fowler, David E. Cohn

Published in: Familial Cancer | Issue 4/2009

Abstract

Currently, three prediction models are used to predict a patient’s risk of having Lynch syndrome (LS). These models have been validated in probands with colorectal cancer (CRC), but not in probands presenting with endometrial cancer (EMC). Thus, the aim was to determine the performance of these prediction models in women with LS presenting with EMC. Probands with EMC and LS were identified. Personal and family history was entered into three prediction models, PREMM(1,2), MMRpro, and MMRpredict. Probabilities of mutations in the mismatch repair genes were recorded. Accurate prediction was defined as a model predicting at least a 5% chance of a proband carrying a mutation. From 562 patients prospectively enrolled in a clinical trial of patients with EMC, 13 (2.2%) were shown to have LS. Nine patients had a mutation in MSH6, three in MSH2, and one in MLH1. MMRpro predicted that 3 of 9 patients with an MSH6, 3 of 3 with an MSH2, and 1 of 1 patient with an MLH1 mutation could have LS. For MMRpredict, EMC coded as “proximal CRC” predicted 5 of 5, and as “distal CRC” three of five. PREMM(1,2) predicted that 4 of 4 with an MLH1 or MSH2 could have LS. Prediction of LS in probands presenting with EMC using current models for probands with CRC works reasonably well. Further studies are needed to develop models that include questions specific to patients with EMC with a greater age range, as well as placing increased emphasis on prediction of LS in probands with MSH6 mutations.

Lynch HT, de la Chapelle A (1999) Genetic susceptibility for non-polyposis colorectal cancer. J Med Genet 36:801–818PubMed

Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851–1860CrossRefPubMed

Hampel H, Frankel W, Panescu J et al (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810–7817CrossRefPubMed

Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129(2):415–421PubMed

Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218CrossRefPubMed

Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456CrossRefPubMed

Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE (2000) Sensitivity and specificity of clinical criteria for non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 37:641–645CrossRefPubMed

Ramsoekh D, Wagner A, van Leerdam ME et al (2008) A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut 57(11):1539–1544CrossRefPubMed

Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRef

10.

Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293(16):1986–1994CrossRefPubMed

11.

Balmana J, Stockwell DH, Steyerberg E et al (2006) Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296:1469–1478CrossRefPubMed

12.

Chen S, Wang W, Lee S et al (2006) Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296:1479–1487CrossRefPubMed

13.

Barnetson RA, Tenesa A, Farrington SM et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354:2751–2763CrossRefPubMed

14.

Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269CrossRefPubMed

15.

Lu KH, Dinh M, Kohlmann W et al (2005) Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105(3):569–574PubMed

16.

Wijnen J, de Leeuw W, Vasen H, van der Klift H, Møller P (1999) Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 23:142–144CrossRefPubMed

17.

Lipton LR, Johnson V, Cummings C et al (2003) Refining the Amsterdam criteria and Bethesda guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol 21(23):4364–4370CrossRef

18.

Devlin LA, Graham CA, Price JH, Morrison PJ (2008) Germline MSH6 mutations are more prevalent in endometrial cancer patient cohorts than hereditary non polyposis colorectal cancer cohorts. Ulster Med J 77(1):25–30PubMed

19.

Wagner A, Hendriks Y, Meijers-Heijboer EF et al (2001) Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 38(5):318–322CrossRefPubMed

20.

Hendriks YM, Wagner A, Morreau H et al (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutation. Gastroenterology 64:4721–4727

21.

Geary J, Sasieni P, Houlston R et al (2008) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7(2):163–172CrossRefPubMed

22.

Plaschke J, Engel C, Krüger S, Holinski-Feder E, Pagenstecher C, Mangold E (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol 22:4486–4494CrossRefPubMed

23.

Kolodner RD, Tytell JD, Schmeits JL et al (1999) Germ-line MSH6 mutations in colorectal cancer families. Cancer Res 59:5068–5074PubMed

Title: Are prediction models for Lynch syndrome valid for probands with endometrial cancer?
Authors: Floor J. Backes
Heather Hampel
Katherine A. Backes
Luis Vaccarello
George Lewandowski
Jeffrey A. Bell
Gary C. Reid
Larry J. Copeland
Jeffrey M. Fowler
David E. Cohn
Publication date: 01-12-2009
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-009-9273-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

A high frequent BRCA1 founder mutation identified in the Greenlandic population

The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30

The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women

Mutation screening of VHL gene in a family with malignant bilateral pheochromocytoma: from isolated familial pheochromocytoma to von Hippel-Lindau disease

Association of MUTYH and MSH6 germline mutations in colorectal cancer patients

Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals

Keynote webinar | Spotlight on antibody–drug conjugates in cancer